First-in-class monoclonal antibody drug for treating immune disorders.Visit Website Scroll Down
KiRA Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders.
Led by experienced industry leaders in immunology drug development, including Dan Baker, Mike Grissinger, and Jim Updike, this team uses their extensive expertise to advance this specialised field of patient treatment. Dan Baker, who served as Senior VP Immunology R&D at Janssen, was responsible for the development of top-selling immunology drugs Remicade, Stelera, and Simponi. He teamed up with Mike Grissinger, who was the head of immunology business development at Janssen, to form KiRA Biotech.
The company aims to revolutionize the treatment of autoimmune diseases by utilizing their expertise and insights to match the right drug to the right patient through the design of effective clinical trial programs. KiRA Biotech is building a pipeline of first-in-class and best-in-class antibody drug candidates for the treatment of autoimmune diseases.